In this infographic we take a look at the long-acting formulations for HIV prevention and treatment currently in the clinical pipeline – from Phase I to approval.
Browsing: Clinical Trial
Take a look at this month’s industry headlines including results for Takeda’s dengue vaccine, approvals for Merck’s Ebola vaccine and the advent of a siderophore antibiotic – the first of this kind.
In this interview we speak to Keith Kaye, from the University of Michigan (MI, USA) about the RESTORE-IMI 2 study, its results and why ICU patients represent an unmet need.
A clinical trial conducted in sub-Saharan African countries over 3 years, has revealed a candidate vaccine for tackling tuberculosis. The candidate vaccine, M72/AS01E, was reported to be 54% effective at preventing active pulmonary tuberculosis disease.
Take a look at this month’s industry headlines including US FDA approvals for XOFLUZATM and…
US FDA approvals for antibiotic Xenleta™ and tuberculosis drug Pretomanid: August’s industry headlines
Take a look at this month’s industry headlines including US FDA approvals for two drugs – Xenleta™ and Pretomanid – in addition to an EMA decision for Zerbaxa®, partnerships for vaccine development and results on Ebola therapeutics.
Xenleta™ (lefamulin), developed by Nabriva Therapeutics, has been approved by the US FDA for adults with community-acquired bacterial pneumonia, marking the first new antibiotic with a novel mechanism of action to be approved in nearly two decades.
The US FDA has approved Pretomanid tablets in combination with bedaquiline and linezolid for the treatment of specific types of drug-resistant pulmonary tuberculosis.
A study of four Ebola therapeutics demonstrated that two drugs showed significantly improved survival rates, leading to the trial being halted early.
The first chlamydia vaccine to reach Phase I clinical trials has been observed to be safe and immunogenic in 35 women.